Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 79,237 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 2 Clear all
Completed Phase 4 Interventional Results available

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

NCT01327547
View directory record Official record
Conditions
HIV Coinfection
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
24
States / cities
Bakersfield, California • Los Angeles, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 30, 2026, 8:10 PM EDT
Terminated Phase 1Phase 2 Interventional

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

NCT01573338
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Roniciclib (BAY1000394), Etoposide, Cisplatin, Carboplatin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
St Louis, Missouri • Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

NCT04145349
View directory record Official record
Conditions
Desmoplastic Small Round Cell Tumor
Interventions
Ramucirumab, Cyclophosphamide, Vinorelbine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Months to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

NCT05084638
View directory record Official record
Conditions
Relapse Remitting Multiple Sclerosis
Interventions
Ofatumumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 35 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
35
States / cities
Chandler, Arizona • Phoenix, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Withdrawn Phase 3 Interventional

Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas

NCT00567658
View directory record Official record
Conditions
Larynx Disease
Interventions
Esomeprazole
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 6, 2013 · Synced Oct 30, 2026, 8:10 PM EDT
Recruiting Phase 2 Interventional

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

NCT06607458
View directory record Official record
Conditions
Refractory Metastatic Colorectal Cancer
Interventions
Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab, Trifluridine-tipiracil plus Bevacizumab Alone
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Duarte, California • Santa Monica, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Not applicable Interventional Results available

PROmoting Diabetes Education and Management Through Peer Support and Team Referral

NCT05587348
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Best Practice Advisory, Peer Support, Usual Care
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 3 Interventional Results available

Adjunctive Ziprasidone in the Treatment of Bipolar I Depression

NCT00483548
View directory record Official record
Conditions
Bipolar Disorder, Depression, Bipolar
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
60
States / cities
Chandler, Arizona • Litchfield Park, Arizona • Little Rock, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer

NCT00499655
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, celecoxib, placebo, laboratory biomarker analysis, immunohistochemistry staining method, fluorescence in situ hybridization, mutation analysis, protein expression analysis, gene expression analysis
Drug · Other · Genetic
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 30, 2026, 8:10 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of ADXS11-001 or MEDI4736 Alone or Combination In Cervical or Human Papillomavirus (HPV)+ Head & Neck Cancer

NCT02291055
View directory record Official record
Conditions
Cervical Cancer, Cancer, Head and Neck Cancer
Interventions
ADXS11-001, MEDI4736
Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A 14 Week Study of Mindfulness Effects on Attentional Control in Older Adults

NCT02714426
View directory record Official record
Conditions
Cognitive Aging
Interventions
Mindfulness-inspired treatment, Brain health
Behavioral · Other
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2019 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 2 Interventional Results available

Study of Lamotrigine to Treat Ménière's Disease

NCT02158585
View directory record Official record
Conditions
Meniere's Disease, Ménière's Vertigo, Vertigo, Intermittent, Vertigo, Aural
Interventions
Lamotrigine, Placebo
Drug
Lead sponsor
Dent Neuroscience Research Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Amherst, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 30, 2026, 8:10 PM EDT
Recruiting Not applicable Interventional

Preoperative Comprehensive Geriatric Assessment (CGA) and Postoperative Delirium

NCT07059585
View directory record Official record
Conditions
CGA
Interventions
CGA, control
Behavioral · Other
Lead sponsor
University of Miami
Other
Eligibility
60 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab In Central Nervous System Metastases

NCT02886585
View directory record Official record
Conditions
Brain Metastases
Interventions
Pembrolizumab, MRI, PET/CT, Stereotactic Radiosurgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Not applicable Interventional

Transcutaneous Electrical Spinal Cord Stimulation for Lower Limbs

NCT01949285
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Transcutaneous Electrical Spinal Cord Stimulation
Device
Lead sponsor
NeuroEnabling Technologies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 4 Interventional Results available

Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism

NCT00452543
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence
Interventions
acamprosate, escitalopram, Medical management, Placebo
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 30, 2026, 8:10 PM EDT
Not listed Not applicable Interventional

Use of 48 Hour Course of Antibiotics to Prevent Surgical Site Infection in Obese Patients Undergoing Cesarean Delivery

NCT01194115
View directory record Official record
Conditions
Surgical Site Infection in Obese Women Undergoing C-section
Interventions
cephalexin & metronidazole, placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
13 Years and older · Female only
Enrollment
475 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 11, 2011 · Synced Oct 30, 2026, 8:10 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

NCT06328608
View directory record Official record
Conditions
Fabry Disease
Interventions
PRX-102 1 mg/kg every two weeks
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
6
States / cities
Phoenix, Arizona • Atlanta, Georgia • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 8:10 PM EDT
Not listed Phase 4 Interventional

Liposomal Bupivacaine Intercostal Nerve Block vs Thoracic Epidural for Regional Analgesia in Multiple Rib Fractures

NCT03574376
View directory record Official record
Conditions
Trauma, Trauma Injury, Pain, Acute
Interventions
Bupivacaine Liposome Injection, Bupivacaine
Drug
Lead sponsor
Chadrick Evans
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 3 Interventional

American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm

NCT00259376
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Dronedarone (SR33589), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 15, 2010 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Not applicable Interventional

Pain Control After Trauma

NCT00739076
View directory record Official record
Conditions
Trauma
Interventions
Virtual Reality
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
12 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 30, 2026, 8:10 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

NCT06054217
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
Interventions
Vehicle of TP-03
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Northridge, California • Shelby, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

NCT02572817
View directory record Official record
Conditions
Influenza A Virus Infection
Interventions
High-titer anti-influenza plasma, Low-titer anti-influenza plasma
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Weeks and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
30
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 30, 2026, 8:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants

NCT04655040
View directory record Official record
Conditions
Healthy Participants
Interventions
Caffeine, Ritlecitinib
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 30, 2026, 8:10 PM EDT